Evidence map›Paper›PMID 32687852›Full record

ArticleJournal of molecular and cellular cardiology2020

Using "old" medications to fight new COVID-19: Re-purposing with a purpose.

Yibin Wang, Roger Foo, Thomas Thum

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular and cellular cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yibin WangDepartment of Anesthesiology, Medicine and Physiology, David Geffen School of Medicine, University of California at Los Angeles, California, USA.
Roger FooGenome Institute of Singapore, Cardiovascular Research Institute, National University of Singapore, Centre for Translational Medicine, Singapore, Singapore.
Thomas ThumInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; REBIRTH Center of Translational Regenerative Medicine, Hannover Medical School, Hanover, Germany.. Electronic address: thum.thomas@mh-hannover.de.

Funding

BCAA Catabolic Defect in HF: Novel Mechanism and Therapeutic TargetR01HL140116 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, ZHAOPING · 2018 to 2021
$1.6M
NHLBI NIH HHS R01 HL140116
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenosine MonophosphateAlanineAngiotensin-Converting Enzyme InhibitorsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19DexamethasoneDiabetes MellitusDrug RepositioningHost-Pathogen InteractionsHumansHydroxychloroquineHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasHypertensionAdenosine MonophosphateAlanineAngiotensin-Converting Enzyme InhibitorsAntiviral AgentsDexamethasoneHydroxychloroquineHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsremdesivirACE inhibitorsCOVID-19Drug treatmentInflammationSARS-CoV-2

Identifiers

PMID32687852
PMCPMC7367776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.